Search
Imlunestrant
go.drugbank.com/drugs/DB19043ApprovedInvestigationalprogression on at least one line of endocrine therapy. … The FDA approved imlunestrant on September 25, 2025 [L54051] as a treatment for estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer with
Synonyms: (5r)-5-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-8-(trifluoromethyl)-5h-(1)benzopyrano(4,3-c)quinolin-2-ol, 5h-(1)benzopyrano(4,3-c)quinolin-2-ol, 5-(4-(2-(3-(fluoromethyl)-1-azetidinyl)ethoxy)phenyl)-8-(trifluoromethyl)-, (5r)-Letermovir
go.drugbank.com/drugs/DB12070ApprovedInvestigationalLetermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients. … [L1021] It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors.[A31290] Letermovir has recieved both priority and orphan drug status from the FDA.
Products: PREVYMIS 240 MG SOLUCIÓN INYECTABLE, PREVYMİS 240 MG FİLM KAPLI TABLET, 28 ADETLovotibeglogene autotemcel
go.drugbank.com/drugs/DB18680ApprovedInvestigationalhave a history of vaso-occlusive events. … [A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who
N-acetyltyrosine
go.drugbank.com/drugs/DB11102ApprovedInvestigationalIt is typically administered as a source of nutritional support where oral nutrition is inadequate or cannot be tolerated. … N-acetyltyrosine is administered as parenteral nutrition or intravenous infusion due to its enhanced solubility compared to tyrosine [A32652].
Dronedarone
go.drugbank.com/drugs/DB04855ApprovedInvestigationalIt is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of the underlying disease. … A safety concern for the risk of drug-induced hepatocellular injury has been issued following marketing of dronedarone.[L8800]
Products: MULTAQ (400 MG), MULTAQ 400 MG FILM-COATED TABLETSElafibranor
go.drugbank.com/drugs/DB05187ApprovedInvestigational[L50768] On June 10, 2024, elafibranor was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis (PBC). … [L50773] The drug was also approved by the EMA on September 23, 2024.[L51878]
Enasidenib
go.drugbank.com/drugs/DB13874ApprovedInvestigationalPatients eligible for this treatment are selected by testing the presence of IDH2 mutations in the blood or bone marrow. … Food and Drug Administration on August 1, 2017.
Synonyms: 2-Methyl-1-(4-(6-(trifluoromethyl)pyridin-2-yl)-6-(2-(trifluoromethyl)pyridin-4-ylamino)-1,3,5-triazin-2-ylamino)propan-2-olColistin
go.drugbank.com/drugs/DB00803ApprovedInvestigationalIt is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes.
Products: APSASOL COLISTIN Powder 100 mg/g, TP-COLIS 2MIU/G POWDERBromocriptine
go.drugbank.com/drugs/DB01200ApprovedInvestigationalWithdrawnBromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as the treatment of acromegaly. … In 1995, the FDA withdrew the approval of bromocriptine mesylate for the prevention of physiological lactation after finding that bromocriptine was not shown to be safe for use.
Categories: Heterocyclic Compounds with 4 or More RingsProducts: Nu-bromocriptine, PARLODEL 2.5 MGStiripentol
go.drugbank.com/drugs/DB09118ApprovedInvestigational[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzymes. … [A250825] However, its clinical efficacy as adjunctive therapy for epilepsies stems from its inhibitory action on CYP enzymes, as stiripentol reduces the degradation of CYP-sensitive antiepileptic drugs
Synonyms: 1-(1,3-Benzodioxol-5-yl)-4,4-dimethyl-1-penten-3-ol, 4,4-Dimethyl-1-((3,4-methylenedioxy)phenyl)-1-penten-3-ol